TY - JOUR
T1 - A Genome-Wide Association Study of IVGTT-Based Measures of First Phase Insulin Secretion Refines the Underlying Physiology of Type 2 Diabetes Variants
AU - Wood, Andrew R
AU - Jonsson, Anna
AU - Jackson, Anne U.
AU - Wang, Nan
AU - van Leewen, Nienke
AU - Palmer, Nicholette D.
AU - Kobes, Sayuko
AU - Deelen, Joris
AU - Boquete-Vilarino, Lorena
AU - Paananen, Jussi
AU - Stančáková, Alena
AU - Boomsma, Dorret I.
AU - de Geus, Eco J. C.
AU - Eekhoff, Elisabeth M. W.
AU - Fritsche, Andreas
AU - Kramer, Mark H. H.
AU - Nijpels, Giel
AU - Simonis-Bik, Annemarie M. C.
AU - van Haeften, Timon W.
AU - Mahajan, Anubha
AU - Boehnke, Michael
AU - Bergman, Richard N.
AU - Tuomilehto, Jaakko
AU - Collins, Francis S.
AU - Mohlke, Karen L.
AU - Banasik, Karina
AU - Groves, Christopher J.
AU - McCarthy, Mark I.
AU - Pearson, Ewan R
AU - Natali, Andrea
AU - Mari, Andrea
AU - Buchanan, Thomas A.
AU - Taylor, Kent D.
AU - Xiang, Anny H
AU - Gjesing, Anette P.
AU - Grarup, Niels
AU - Eiberg, Hans
AU - Pedersen, Oluf
AU - Chen, Yii-Derr
AU - Laakso, Markku
AU - Norris, Jill M.
AU - Smith, Ulf
AU - Wagenknecht, Lynne E.
AU - Baier, Leslie
AU - Bowden, Donald W.
AU - Hansen, Torben
AU - Walker, Mark
AU - Watanabe, Richard M.
AU - 't Hart, Leen M.
AU - Hanson, Robert L.
AU - Frayling, Timothy M.
N1 - A.R.W. and T.M.F. are supported by a European Research Council grant (SZ-245 50371-GLUCOSEGENES-FP7-IDEAS-ERC). R.L.H., S.K. and L. Baier are supported by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases. This work was in part funded by the Innovative Medicines Initiative Joint Undertaking under grant agreement No. 115317 (DIRECT), resources of which are composed of financial contributions from the European Union's Seventh Framework Programme (FP7/2007-2013), and European Federation of Pharmaceutical Industries and Associations (EFPIA) companies’ in kind contribution (http://www.direct-diabetes.org/); the Netherlands Organization for Health Research and Development (Priority Medicines Elderly Program 113102006); The Netherlands Twin Register, part of the HCC cohort, is supported by the European Research Council (grant 230374), by BBMRI-NL, a Research Infrastructure financed by the Dutch government (NWO 184.021.007) and the Netherlands Organization for Scientific Research (grant NWO 480-04-004, NWO/SPI 56-464-14192). The RISC Study was supported by European Union grant QLG1-CT-2001 01252 and AstraZeneca. The initial genotyping of the RISC samples was funded by Merck & Co Inc. This research was supported by the National Institutes of Health: IRASFS (HL060944, HL061019, HL060919,and HG007112) and the GUARDIAN Consortium (DK085175). The provision of genotyping data was supported in part by UL1-TR-000124 (Clinical and Translational Science Institute) and DK063491. Computing resources were provided in part by the Wake Forest School of Medicine Center for Public Health Genomics. Support for FUSION was provided by NIH grants R01-DK062370 (to M.B.), R01-DK072193 (to K.L.M.), and intramural project number 1Z01-HG000024 (to F.S.C.). Genotyping was conducted by the Johns Hopkins University Genetic Resources Core Facility SNP Center at the Center for Inherited Disease Research (CIDR), with support from CIDR NIH contract no. N01-HG-65403.
PY - 2017/7/21
Y1 - 2017/7/21
N2 - Understanding the physiological mechanisms by which common variants predispose to type 2 diabetes requires large studies with detailed measures of insulin secretion and sensitivity. Here we performed the largest genome-wide association study of first phase insulin secretion, as measured by intravenous glucose tolerance tests, using up to 5,567 non-diabetic individuals from 10 studies. We aimed to refine the mechanisms of 178 known associations between common variants and glycaemic traits and identify new loci. Thirty type 2 diabetes, or fasting glucose raising, alleles were associated with a measure of first phase insulin secretion at P<0.05, and provided new evidence, or the strongest evidence yet, that insulin secretion, intrinsic to the islet cells, is a key mechanism underlying the associations at the HNF1A, IGFBP2, KCNQ1, HNF1B, VPS13C/C2CD4A, FAF1, PTPRD, AP3S2, KCNK16, MAEA, LPP, WFS1 and TMPRSS6 loci. The fasting glucose raising allele near PDX1, a known key insulin transcription factor, was strongly associated with lower first phase insulin secretion but has no evidence for an effect on type 2 diabetes risk. The diabetes risk allele at TCF7L2 was associated with a stronger effect on peak insulin response than on C-peptide-based insulin secretion rate, suggesting a possible additional role in hepatic insulin clearance or insulin processing. In summary, our study provides further insight into the mechanisms by which common genetic variation influences type 2 diabetes risk and glycaemic traits.
AB - Understanding the physiological mechanisms by which common variants predispose to type 2 diabetes requires large studies with detailed measures of insulin secretion and sensitivity. Here we performed the largest genome-wide association study of first phase insulin secretion, as measured by intravenous glucose tolerance tests, using up to 5,567 non-diabetic individuals from 10 studies. We aimed to refine the mechanisms of 178 known associations between common variants and glycaemic traits and identify new loci. Thirty type 2 diabetes, or fasting glucose raising, alleles were associated with a measure of first phase insulin secretion at P<0.05, and provided new evidence, or the strongest evidence yet, that insulin secretion, intrinsic to the islet cells, is a key mechanism underlying the associations at the HNF1A, IGFBP2, KCNQ1, HNF1B, VPS13C/C2CD4A, FAF1, PTPRD, AP3S2, KCNK16, MAEA, LPP, WFS1 and TMPRSS6 loci. The fasting glucose raising allele near PDX1, a known key insulin transcription factor, was strongly associated with lower first phase insulin secretion but has no evidence for an effect on type 2 diabetes risk. The diabetes risk allele at TCF7L2 was associated with a stronger effect on peak insulin response than on C-peptide-based insulin secretion rate, suggesting a possible additional role in hepatic insulin clearance or insulin processing. In summary, our study provides further insight into the mechanisms by which common genetic variation influences type 2 diabetes risk and glycaemic traits.
KW - Journal article
U2 - 10.2337/db16-1452
DO - 10.2337/db16-1452
M3 - Article
C2 - 28490609
SN - 0012-1797
VL - 66
SP - 2296
EP - 2309
JO - Diabetes
JF - Diabetes
IS - 8
ER -